Improving tumor immunity in breast cancer through targeted therapy
Targeting Focal Adhesion Kinase to Improve RT-inducted Tumor Immunity
['FUNDING_R01'] · WASHINGTON UNIVERSITY · NIH-10836419
This study is looking at how blocking a protein called FAK can help your immune system better fight breast cancer, especially when combined with radiation therapy, so you might have a more effective treatment option.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-10836419 on ClinicalTrials.gov |
What this research studies
This research investigates how targeting Focal Adhesion Kinase (FAK) can enhance the immune response against breast cancer tumors, particularly in the context of radiation therapy. The approach focuses on understanding the tumor microenvironment, which is often resistant to treatment due to factors like dense collagen and low oxygen levels. By inhibiting FAK, the study aims to reduce tumor-associated fibrosis and improve the effectiveness of both chemotherapy and immunotherapy. Patients may benefit from a more effective treatment strategy that harnesses their immune system to fight cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with breast cancer who are undergoing or considering radiation therapy.
Not a fit: Patients with non-breast cancer malignancies or those who are not receiving radiation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment outcomes for breast cancer patients by enhancing their immune response to tumors.
How similar studies have performed: Previous studies have shown promising results in targeting FAK to improve responses to cancer therapies, indicating that this approach may be effective.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DENARDO, DAVID G — WASHINGTON UNIVERSITY
- Study coordinator: DENARDO, DAVID G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer, Cancers, neoplasm/cancer